Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 9Recurrence 4Breast Neoplasms 4Advanced Solid Tumors 4Solid Tumor 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Medical Oncology 2Lymphoma, Follicular 2Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Mesothelioma 1

Interventions

Cisplatin 9pembrolizumab 7Irinotecan 7Radiotherapy 6Fluorouracil 6Docetaxel 5spartalizumab 4Oxaliplatin 4130-nm albumin-bound paclitaxel 4Nivolumab 3Carboplatin 3toripalimab 2tislelizumab 2elgemtumab 2durvalumab 2Radiation 2Paclitaxel 2Leucovorin 2Gemcitabine 2Drug Therapy 2vandetanib 1tremelimumab 1ribociclib 1palbociclib 1obinutuzumab 1nedaplatin 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1dalpiciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Squamous Cell Carcinoma × Itraconazole × Clear all
NCT06084481 2026-01-20

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

AbbVie

Phase 1 Active not recruiting
302 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡